Gilead Sciences, Inc. (GILD) operating KPIs
GILDNasdaqBiological Products, (No Diagnostic Substances)Fiscal year ends December 31
Financials through Q2 FY2026, quarter ended Jun 30, 2026Last filing: 10-Q on Aug 6, 2026Score 11/30105% above fair value
$170.68+5.07 (+3.06%)
Close on Oct 30, 2026Market cap $211.64BP/E –Yield 1.85%
Gilead Sciences total Oncology Franchise Product Sales — Worldwide YoY growth (%) (%)
Form 8-K Total Revenue Summary
Latest, FY2025
-2.0%
Period ended Dec 31, 2025
Change on a year earlier
-14.0 pts
12.0% in FY2024
History
3 years
Since FY2023
Sources
3
Documents cited below
Annual history
Hover a value to see the sentence it was read from; calculated values show their formula
| Period | Ended | Total Oncology Franchise Product Sales — Worldwide YoY growth (%) (%) | Year on year | Source |
|---|---|---|---|---|
| FY2025 | Dec 31, 2025 | -2.0% | -14.0 pts | Form 8-K (exhibit991earningspressrel.htm, filed 2026-02-10) ↗ |
| FY2024 | Dec 31, 2024 | 12.0% | -25.0 pts | Form 8-K (exhibit991earningspressrel.htm, filed 2025-02-11) ↗ |
| FY2023 | Dec 31, 2023 | 37.0% | – | Form 8-K (exhibit991earningspressrel.htm, filed 2024-02-06) ↗ |
Cite this data
StockData. (2026). Gilead Sciences Total Oncology Franchise Product Sales — Worldwide YoY growth (%) (%), annual FY2023–FY2025 [Data set]. Compiled from Gilead Sciences SEC filings and investor materials. https://stockdatahq.com/stocks/gild/kpis/onc_total_yoy
See every metric in the Gilead Sciences KPI table. Data updated Oct 29, 2026.